All In MedTech

Device Trial Radar · NCT06733246

Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients

Evaluation of the Safey & Performance of the Ceretrieve Device Designed for Thrombus Removal in Intracranial Arteries Using an Aspiration Technique in Patients Suffering an Acute Ischemic Stroke (AIS)

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Nov 12, 2024

Primary completion

May 30, 2027

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Ceretrieve Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Dec 13, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure. This means to assess that the use with the Ceretrieve neuro-thrombectomy device that is designed to treat acute ischemic stroke patients raises no safety concerns and that it is found to be effective when it is used according to its intended purpose, which is revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (involving the internal carotid artery, middle cerebral artery- M1 and M2 segments, basilar, and vertebral arteries). The study researchers will compare the efficacy and safety results of this study to data derived from the literature of FDA approved neuro-thrombectomy devices. The study hypothesis is that The Ceretrieve device would achieve successful reperfusion performance shall be similar to the safety \& performance derived from the literature. The primary outcomes that will be measures are: Performance: Successful reperfusion, defined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia (mTICI) score 2b-3 within three passes of the Ceretrieve system without any rescue. Safety: Symptomatic intra-cranial hemorrhage within 24 (18-36) hours of the study procedure. Patients who will participate in this study will be followed for a time period of 3 months. After discharge from the medical center, they will be asked to arrive to a one visit at the clinic for safety data collection and evaluation.

Conditions

  • Acute Ischemic Stroke

Interventions

  • Aspiration 0Device

    Ceretrieve is a neuro-thrombectomy aspiration catheter deigned for clot removal in AIS patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Successful Reperfusion (mTICI 2b-3) Within Three Passes Without Rescue TherapyTime frame: intra-procedural
  2. Number of Participants With Symptomatic Intracranial Hemorrhage Within 24 (18-36) Hours Post-ProcedureTime frame: 24 (18-36) hours post procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Heidelberg University Hospital

    Heidelberg, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.